Abstracts Archive - Page 2096 of 2425 - ACR Meeting Abstracts

Abstract Number: 2345 • 2013 ACR/ARHP Annual Meeting
Long-Term Targeted Safety Event Rates In RA Patients Following Initiation Of Rituximab: Interim Analysis From Sunstone Registry
Kenneth G. Saag¹, Kevin L. Winthrop², Kimberly Alexander³, Steven Francom⁴ and Daniel Furst⁵, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ³Epidemiology, Genentech, Inc., South San Francisco, CA, ⁴Genentech, Inc., South San Francisco, CA, ⁵Rheumatology, UCLA, Los Angeles, CA
Background/Purpose: Rituximab (RTX) is used for the treatment of rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti-TNF therapy (TNF-IR). Long-term safety…
Abstract Number: 2346 • 2013 ACR/ARHP Annual Meeting
Effects Of Tofacitinib, An Oral Janus Kinase Inhibitor, On Work Limitations In Patients With Rheumatoid Arthritis
Vibeke Strand¹, Keith S. Kanik², Carol Connell², Bethanie Wilkinson², David Gruben² and Gene Wallenstein², ¹Stanford University, Palo Alto, CA, ²Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Participation, in particular work productivity, is increasingly recognized as…
Abstract Number: 2347 • 2013 ACR/ARHP Annual Meeting
Functional Single Nucleotide Polymorphisms In The Interferon-γ and The NLRP3 (Cryopyrin) Genes Associated With Anti-TNF Response In Danish Rheumatoid Arthritis Patients
Jacob Sode^1,2,3, Niels H. H. Heegaard⁴, Henning Locht², Ulla Vogel⁵, Steffen Bank^6,7, Merete Lund Hetland^8,9 and Vibeke Andersen^3,7,10,11, ¹Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen S, Denmark, ²Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ³Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁴Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, ⁵National Research Centre for the Working Environment, Copenhagen, Denmark, ⁶Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, ⁷Medical Department, Viborg Regional Hospital, Viborg, Denmark, ⁸The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, ⁹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ¹⁰Medical Department, Hospital of Southern Jutland Aabenraa, Aabenraa, Denmark, ¹¹Odense University Hospital, OPEN (Odense Patient data Explorative Network), Odense, Denmark
Background/Purpose: Most patients with rheumatoid arthritis (RA) benefit from tumor necrosis factor-a blocking treatment (anti-TNF). About 1/3, however, do not respond to this costly and…
Abstract Number: 2348 • 2013 ACR/ARHP Annual Meeting
Long Term Safety Of Intravenous Golimumab and Comparisons With Subcutaneous Golimumab In Rheumatologic Conditions: Results From The 120-Day Safety Report Of a Phase 3 Trial Of Intravenous Golimumab
Rene Westhovens¹, Clifton O. Bingham III², Michael E. Weinblatt³, Roy Fleischmann⁴, Edward C. Keystone⁵, Elizabeth C. Hsia⁶, Benjamin Hsu⁶, Lilianne Kim⁶, Surekha Mudivarthy⁶, Michael Mack⁷, Neil Goldstein⁶, Jürgen Braun⁸, Arthur Kavanaugh⁹, Alan M. Mendelsohn¹⁰ and Jonathan Kay¹¹, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁸PsAID taskforce, EULAR, Zurich, Switzerland, ⁹University of California San Diego, San Diego, CA, ¹⁰Immunology, Janssen Research & Development, LLC., Spring House, PA, ¹¹UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA
Background/Purpose: To describe safety profile of IV GLM in RA from the Ph3 GLM IV program. AE rates of interest are indirectly compared to…
Abstract Number: 2349 • 2013 ACR/ARHP Annual Meeting
Abatacept and Anti-Tumor Necrosis Factor Monoclonal Antibodies: Efficacy and Safety Comparisons
M Schiff¹, Maxime Dougados², Roy Fleischmann³, J Fay⁴ and M Maldonado⁴, ¹University of Colorado, Denver, CO, ²Rheumatology, Hopital Cochin, Descartes University, Paris, France, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: A paucity of clinical trial data exists comparing the efficacy and safety of biologic therapies for RA. This study evaluated remission rates and safety…
Abstract Number: 2350 • 2013 ACR/ARHP Annual Meeting
Effects Of VX-509, An Investigational Oral Selective Janus Kinase 3 (JAK3) Inhibitor, On Patient-Reported Outcomes In a Phase 2A Study Of Patients With Active Rheumatoid Arthritis
Vibeke Strand¹, Ellison Suthoff², Roy Fleischmann³, Montserrat Vera-Llonch⁴, John Jiang², Yanqiong Zhang² and Nils Kinnman⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Vertex Pharmaceuticals Incorporated, Cambridge, MA, ³Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Vertex Pharamceuticals Incorporated, Cambridge, MA, ⁵Vertex Pharmaceuticals Incorporated, Eysins, Switzerland
Background/Purpose: VX-509 is an oral JAK3 inhibitor being evaluated as a treatment for RA. Safety and efficacy results from a phase 2a, 12-week, randomized…
Abstract Number: 2312 • 2013 ACR/ARHP Annual Meeting
Experiences Of Older People Living With Ankylosing Spondylitis
Jane Martindale, Elham Kashefi and Lynne Goodacre, Faculty of Health and Medicine, Lancaster University, Lancaster, United Kingdom
Background/Purpose: With an increasing demographic of ageing, more people may be living longer with a long-term health condition. There may be implications in terms of…
Abstract Number: 2310 • 2013 ACR/ARHP Annual Meeting
Nurse Training; Confidence and Competence For Educating Patients Commencing Methotrexate Therapy
Sandra M. Robinson¹, Andrew Hassell², Sarah Ryan³, Nicola Adams⁴, Peta S. Heslop¹ and David Walker⁵, ¹R&D, North Tyneside General Hospital, North Shields, United Kingdom, ²Rheumatology, School of Medicine (Keele Campus), Keele, United Kingdom, ³Keele University, Staffordshire, United Kingdom, ⁴Rehabilitation, Northumbria University, Newcastle Upon Tyne, United Kingdom, ⁵Dept of Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Background/Purpose: The education of patients is a central part of the nursing role in the UK. Nowhere is it more important than in relation to…
Abstract Number: 2311 • 2013 ACR/ARHP Annual Meeting
Impact Of Healing Architecture In a Rheumatology Outpatient Clinic
Gunhild Bukh¹, Erik Kehn Jensen², Anne Marie Munk Tommerup³ and Ole Rintek Madsen⁴, ¹Dept. of Rheumatology, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Kehn & Warnøe, Copenhagen, Denmark, ³Danish Architecture Centre, Copenhagen, Denmark, ⁴Copenhagen University Hospital Gentofte, Copenhagen, Denmark
Background/Purpose: Healing Architecture (HA) is a design concept primarily aimed at reducing factors of stress in the physical environment both for the patient and for…
Abstract Number: 2313 • 2013 ACR/ARHP Annual Meeting
Pain-Related Anxiety As a Barrier To Use Of Methotrexate In Rheumatoid Arthritis: Comparing Conventional Vial, Needles, and Syringe With An Investigational Auto-Injector In Healthy Volunteers
Victoria L. Ruffing¹ and Kaushik J. Dave², ¹Medicine JHAAC, Johns Hopkins University, Baltimore, MD, ²Product Development, Antares Pharma Inc, Ewing, NJ
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. Limitations of systemic exposure of oral MTX can affect its efficacy. Subcutaneous (SC) MTX…
Abstract Number: 2315 • 2013 ACR/ARHP Annual Meeting
Reducing The Need For Total Knee Arthroplasty: The Experience Of a Multidisciplinary Osteoarthritis Clinic
Caroline Jones¹, Angelo Papachristos¹ and Laurence A. Rubin², ¹Physiotherapy, St Michael's Hospital, Toronto, ON, Canada, ²Rheumatology, St. Michael Hospital, Toronto, ON, Canada
Background/Purpose: St. Michael’s Hospital (SMH) is a tertiary care facility located in Toronto, serving a diverse social, economic and cultural urban population. In 2008, a…
Abstract Number: 2316 • 2013 ACR/ARHP Annual Meeting
Anti-Human TNF-Alpha Domain Antibody Construct, CEP-37247/Placulumab, Is As Efficacious As Other Leading TNF-Alpha-Blockade Therapies in a Humanized Mouse Model of Rheumatoid Arthritis
Matthew M. Seavey¹, Linglong Zou², Adam Clarke³, Anthony G. Doyle³, Roberta Weiss⁴, Aric Orbach⁵, Brad McIntyre⁶ and Merav Bassan⁷, ¹Nonclinical Development, Pharmacology, Teva Pharmaceuticals, Inc., West Chester, PA, ²GB&T, Teva Biopharmaceuticals, Rockville, MD, ³Discovery Biologics, Teva Pharmaceuticals, Inc., Sydney, Australia, ⁴Clinical Development, Teva Pharmaceuticals, Inc., Frazer, PA, ⁵Nonclinical Development, Pharmacology, Teva Pharmaceuticals, Inc., Netanya, Israel, ⁶Formulation, Teva Pharmaceuticals, Inc., West Cheater, PA, ⁷Teva R&D - Innovative Project Leadership, Teva Pharmaceuticals, Inc., Netanya, Israel
Background/Purpose: The cytokine tumor necrosis factor (TNF)alpha is a potent pro-inflammatory mediator involved in several autoimmune diseases including rheumatic arthritis and for over a decade…
Abstract Number: 2317 • 2013 ACR/ARHP Annual Meeting
Impact of PVA Coated Nanoparticles On Cellular Viability and Functionality of Immune Cells Obtained From Healthy Donors and Patients With Rheumatoid Arthritis Or Osteoarthritis
Cindy Strehl¹, Timo Gaber¹, Manuela Jakstadt¹, Martin Hahne¹, Saskia Schellmann¹, Barbara Szostak¹, Géraldine Coullerez², Heinrich Hofmann², Gerd Burmester³ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Institute of Materials Powder Technology Laboratory, École polytechnique fédérale de Lausanne, Lausanne, Switzerland, ³Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Nanotechnology has developed into a key technology of the 21st century. Over the recent years, the number of nanotechnical products has received an enormous…
Abstract Number: 2318 • 2013 ACR/ARHP Annual Meeting
Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept
Michael E. Weinblatt¹, Joan M. Bathon², Michele Hooper³, Bojena Bitman⁴, Yue Yang⁵, David H. Collier⁶, James Chung⁷ and Mark C. Genovese⁸, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ⁴Amgen, Inc., San Francisco, CA, ⁵Assent Consulting, South San Francisco, CA, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Amgen, Thousand Oaks, CA, ⁸Division of Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Retention rates may be used as a surrogate of long-term effectiveness of drug therapy in open-label studies. Studies have reported that patients (pts)…
Abstract Number: 2319 • 2013 ACR/ARHP Annual Meeting
Comparative Safety Of Biological Agents Among Medicare Rheumatoid Arthritis Patients
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell¹, Lang Chen³, Emily Levitan¹, James Lewis⁴, Kenneth G. Saag⁵, Timothy Beukelman⁶, Kevin L. Winthrop⁷, John Baddley⁸, Paul M. Muntner¹ and Jeffrey R. Curtis³, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁸Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Several new biologic disease-modifying antirheumatic drugs (DMARDs) have been approved for treatment of rheumatoid arthritis (RA) in United States. However, their comparative risks of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].